# ATXI catalysts: AVENUE THERAPEUTICS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/atxi/catalysts

> AVENUE THERAPEUTICS, INC. (ATXI) has no upcoming catalysts in this calendar. The latest recorded is the AVENUE THERAPEUTICS, INC. earnings report, November 14, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | AVENUE THERAPEUTICS, INC. |
| Ticker | ATXI (OTC) |
| SEC CIK | 1644963 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/atxi |

## Cash runway

Cash $1.5M as of 2026-09-30; quarterly burn $422K; about 10.8 months of runway at that rate (XBRL company facts, accession 0001437749-26-035564).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jul 2023 | [AJ201 trial start](https://sec-api.dev/pdufa/aj201) | ATXI |  | completed | "In July 2023, we announced the first patient was dosed in the Phase 1b/2a trial of AJ201." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1644963/000143774925010196/atxi20241231_10k.htm)) |
| late 2024 | [AJ201 topline data readout](https://sec-api.dev/pdufa/aj201) | ATXI | spinal and bulbar muscular atrophy | scheduled | "- Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1644963/000143774924035304/ex_748191.htm)) |
| November 14, 2024 | [AVENUE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/atxi/catalysts) | ATXI |  | completed | "Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1644963/000143774924035304/ex_748191.htm)) |

## Drugs

- [AJ201](https://sec-api.dev/pdufa/aj201): spinal and bulbar muscular atrophy

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/atxi/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ATXI catalysts: AVENUE THERAPEUTICS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/atxi/catalysts

```bibtex
@misc{secapidev_companies_atxi_catalysts_20261116,
  title        = {ATXI catalysts: AVENUE THERAPEUTICS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/atxi/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_atxi_catalysts_20261116","title":"ATXI catalysts: AVENUE THERAPEUTICS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/atxi/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
